重复经颅磁刺激联合抗抑郁药治疗抑郁症:状态依赖机制、临床证据与转化挑战
本文综述了重复经颅磁刺激(rTMS)联合抗抑郁药治疗抑郁症的机制、临床证据与转化挑战。高通量rTMS可能调节皮层兴奋性、单胺能传递、突触可塑性及分布脑网络;联合治疗或可加速早期改善、提高应答与缓解率并降低复发风险,但获益异质且受期望效应与假盲法限制。rTMS与抗抑郁药的交互应视为由药物类别、刺激方案与时机、皮层兴奋性、元可塑性及个体神经生物学背景塑造的状态依赖过程。
要点
- rTMS联合抗抑郁药可能加速早期改善、提高应答与缓解率并降低复发风险。
- 联合治疗获益在患者与症状维度间异质,需考虑期望效应与假盲法局限。
- rTMS与抗抑郁药交互为状态依赖过程,受药物类别、刺激方案与时机等塑造。
核心结论
- rTMS联合抗抑郁药治疗抑郁症的获益应视为状态依赖过程而非 uniformly additive 或协同。
- 联合治疗可能加速早期改善、提高应答与缓解率并降低复发风险,但患者间异质。
研究设计与样本
- 本文为综述,整合机制、神经影像与临床证据,讨论生物标志物、状态与症状导向的靶向及治疗顺序优化。
主要发现
- 高通量rTMS可能调节皮层兴奋性、单胺能传递、突触可塑性与分布脑网络。
- 临床证据提示联合治疗可能加速早期改善、提高应答与缓解率并降低复发风险。
- 联合治疗获益在患者与症状维度间异质,并受期望效应与假盲法局限影响。
- 神经影像发现治疗相关功能与结构改变,包括海马体积变化,但分子信号、环路重组、结构发现与症状改善间因果关系未明。
临床怎么用
- 临床应基于生物标志物、状态与症状信息进行靶向,优化治疗顺序以提升联合治疗的精准性与可及性。
- 评估联合治疗时需考虑药物类别、刺激方案与时机、皮层兴奋性、元可塑性及个体神经生物学背景。
局限性
- 联合治疗获益异质且应结合期望效应与假盲法局限解读。
- 分子信号、环路重组、结构发现与症状改善间因果关系尚未解决。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Depression is a highly prevalent and debilitating mental disorder. Pharmacotherapy remains the primary treatment modality; however, its efficacy is often limited by a delayed onset of action, suboptimal response in some patients, and a high risk of recurrence. Treatment-resistant depression, characterized by poor response to conventional therapies, poses a major clinical challenge and highlights the need for improved treatment strategies. Repetitive transcranial magnetic stimulation (rTMS), a noninvasive neuromodulation technique, has shown promise for depression, particularly when combined with antidepressant pharmacotherapy. Advances in neuroimaging, neurochemistry, and network neuroscience have clarified how high-frequency rTMS may modulate cortical excitability, monoaminergic transmission, synaptic plasticity, and distributed brain networks. Clinical evidence suggests that combined treatment may accelerate early improvement, increase response and remission, and reduce relapse risk; however, these benefits are heterogeneous across patients and symptom domains and should be interpreted in light of expectancy effects and limitations of sham blinding. Neuroimaging studies have identified treatment-associated functional and structural changes, including hippocampal volume changes, but the causal links among molecular signaling, circuit reorganization, structural findings, and symptom improvement remain unresolved. The interaction between rTMS and antidepressants should therefore not be viewed as uniformly additive or synergistic, but as a state-dependent process shaped by medication class, stimulation protocol and timing, cortical excitability, metaplasticity, and individual neurobiological context. This review integrates mechanistic, neuroimaging, and clinical evidence and discusses how biomarker-, state-, and symptom-informed targeting, optimized treatment sequencing, and pragmatic implementation strategies could improve the precision and accessibility of combined treatment for depression.
引用
- Deng J, Shao Y, Jiang L, et al. Repetitive transcranial magnetic stimulation (rTMS) combined with antidepressant pharmacotherapy for depression: state-dependent mechanisms, clinical evidence, and translational challenges. Mol Psychiatry. 2026. PMID: 42894014. doi:10.1038/s41380-026-03930-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。